Science 2018-04-28T13:01:15+00:00

How It Works

OPUS works by combining 7 research-based ingredients that are clinically proven to:

  • Enhance Memory
  • Improve Attention
  • Reduce Anxiety
  • Reduce Stress
  • Improve Mental Performance Under Stress
  • Sustain Working Memory During Multi-tasking
  • Prevent Age-related Cognitive Decline
  • Prevent Irreversible Damage Due to Deficiency

CLINICAL STUDY – ALPHA GPC

PARTICIPANTS: 261
METHOD: Multi-center, double-blind, randomized, placebo-controlled trial
DOSAGE: Alpha-gpc (choline alfoscerate) 400mg x3/day
TIME: 90 days & 180 days
ASSESSMENT: Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), the Mini-Mental State Examination (MMSE), the Global Deterioration Scale (GDS), the Alzheimer’s Disease Assessment Scale-Behavioral Subscale (ADAS-Behav), all items of the Alzheimer’s Disease Assessment Scale (ADAS-Total), and the Clinical Global Impression (CGI) scale
RESULTS: Participants in alpha-gpc group consistently improved after 90 and 180 days. Placebo group remained unchanged or worsened.


CLINICAL STUDY – BACOPA MONNIERA

PARTICIPANTS: 170
METHOD: double-blind, randomized, placebo-controlled trial
DOSAGE: Bacopa monniera 150mg x2/day
TIME: 90 days
ASSESSMENT: Cognitive Drug Research (CDR), Rapid Visual Information-Processing (RVIP)
RESULTS: The Bacopa monniera group showed significantly improved performance on working memory, more specifically spatial working memory accuracy. The number of false-positives recorded in the Rapid Visual Information Processing task was also reduced for the Bacopa monniera group following the treatment period.


CLINICAL STUDY – RHODIOLA ROSEA

PARTICIPANTS: 161
METHOD: double-blind, randomized, placebo-controlled trial
DOSAGE: Rhodiola rosea 185mg 2-3 capsules/day (single dose)
TIME: 90 days
ASSESSMENT: Mann-Whitney test; Three different tests were used to evaluate the capacity for mental work: T1, for the assessment of visual perception and information processing of the “correction test” category; T2, for the evaluation of short-term memory; T3, involving higher mental functions, the perception of order.
RESULTS: The study showed a pronounced anti-fatigue effect on capacity for mental work against a background of fatigue and stress.


CLINICAL STUDY – L-THEANINE & CAFFEINE

PARTICIPANTS: 24
METHOD: Double-blind, randomized, placebo-controlled, balanced crossover
DOSAGE: L-theanine (250mg) & caffeine (150mg)
TIME: 5 study days, 7 days apart; 30 & 90 minute studies
ASSESSMENT: Cognitive Drug Research (CDR), Rapid Visual Information Processing (RVIP), computer-controlled tasks, logical reasoning task, sentence verification task, serial subtractions, Bond–Lader visual analogue scales (mood scales), Caffeine Research Visual Analogue Scales (CRVAS)
RESULTS: Improved RVIP accuracy and mental fatigue ratings; faster simple reaction time, faster numeric working memory reaction time; improved sentence verification accuracy; headache and tired ratings reduced; alert ratings increased; significant positive caffeine & L-theanine interaction on delayed word recognition reaction time.


CLINICAL STUDY – N-ACETYL L-TYROSINE

PARTICIPANTS: 21
METHOD: Randomized, placebo-controlled study
DOSAGE: Tyrosine 2g
TIME: 5 days
ASSESSMENT: Computer tasks – Memory Comparison Task (MCT), a Tracking Task (TT), a Continuous Memory Task (CMT), and Double Task (DT); Profile of Mood States (POMS), State-Trait Anxiety Inventory (STAI)
RESULTS: The number of correct responses on the MCT was significantly higher at the posttest in the tyrosine group than in the placebo group; tyrosine group had a better RMS tracking score on the TT at the posttest than the placebo group; supplementation of tyrosine may reduce the cognitive effects of psychosocial stress and fatigue.


CLINICAL STUDY – PHOSPHATIDYLSERINE

PARTICIPANTS: 18
METHOD: Open trial
DOSAGE: 100mg x3/day (plant-sourced)
TIME: 12 weeks
ASSESSMENT: Memory Complaints Questionnaire (MAC-Q), Mini Mental State Examination (MMSE), Modified Haschinski Ischemia Scale (HIS)
RESULTS: Subjective improvement of memory for daily tasks; Learning rate, name-face association, and facial recognition significantly improved at 6 weeks and maintained at 12 weeks.


CLINICAL STUDY B12 DEFICIENCY

PARTICIPANTS: 121
METHOD: Cross-sectional
TIME: 4.6 years
ASSESSMENT: 17 cognitive function tests, blood samples, MRI brain scans
RESULTS: Methylmalonate levels were associated with poorer episodic memory and perceptual speed, and cystathionine and 2-methylcitrate with poorer episodic and semantic memory. Homocysteine concentrations were associated with decreased total brain volume.

NOOESIS